PAVmed Inc. Raises $15 Million Through Preferred Stock Offering

PAVmed Inc. has successfully raised $15 million through a preferred stock offering by its subsidiary, Lucid Diagnostics Inc. This financing event, effective as of October 21, 2026, involved the sale of 15,000 shares of Series C Convertible Preferred Stock to accredited investors at a price of $1,000 per share. The closing of the transaction occurred on the same day, marking a significant step in strengthening PAVmed's financial position.

The funds raised are expected to enhance Lucid Diagnostics' operational capabilities and support its growth initiatives. This move is particularly notable within the surgical and medical instruments industry, where securing capital can be crucial for innovation and competitive advantage.

Background

PAVmed Inc., incorporated in Delaware, operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company is publicly traded on the Nasdaq under the ticker symbol PAVM. Its recent filings include a Schedule 13G/A on October 23, 2026, and an 8-K on October 22, 2026, detailing this significant financing event.

What the Filing Says

According to the SEC filing, "Effective as of October 21, 2026, Lucid Diagnostics Inc. entered into subscription agreements with certain accredited investors, which provided for the sale to the Investors of 15,000 shares of Lucid Diagnostics’ newly designated Series C Convertible Preferred Stock, par value $0.001 per share, at a purchase price of $1,000 per share." The gross proceeds from this offering amounted to $15 million.

The filing also mentions that on the closing date, Lucid Diagnostics filed a Certificate of Designations with the State of Delaware, which outlines the terms of the Series C Preferred Stock. Additionally, a registration rights agreement was executed, allowing for the resale of shares of common stock that may be issued under the Series C Preferred Stock.

Impact

This capital infusion is likely to impact various stakeholders, including the investors who participated in the offering, as well as the broader surgical and medical instruments industry. Competitors may need to assess their own capital strategies in light of PAVmed's successful fundraising.

What's Next

The filing does not specify what happens next for PAVmed or Lucid Diagnostics following this offering. However, the additional capital could lead to new product developments or expansions in their operational capabilities.